Cardiff Oncology to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences. Details of the presentations can be found below. B. Riley Securities Precision Oncology & Radiopharma ConferencePresenter: Mark Erlander, CEOFormat: Panel discussion on “What It Takes to Move the Needle in Improving R ...